Raimar Löbenberg

Biography

Dr. Löbenberg holds a BSc in pharmacy from the Johannes Gutenberg-University in Mainz, Germany. He received his PhD in pharmaceutics from the Johann Wolfgang Goethe-University in Frankfurt in 1996. He joined the University of Alberta in 2000.  His research interests are in Biopharmaceutics to predict the oral performance of drugs and botanicals and inhalable nanoparticles to treat lung diseases like cancer or tuberculosis.  He is founder and director of the Drug Development and Innovation Centre at the University of Alberta.  He was president of the Canadian Society for Pharmaceutical Sciences 2014 & 2015 He is member of the United States Pharmacopeia Dietary Supplement Expert Committee.  He is Vice Chair of the Specialty Committee of Traditional Chinese Medicine in Pharmaceutics of the World Foundation of Chinese Medicine Science.  He is member of the Health Canada Scientific Advisory Committee on Pharmaceutical Sciences and Clinical Pharmacology. Dr. Löbenberg holds a BSc in pharmacy from the Johannes Gutenberg-University in Mainz, Germany. He received his PhD in pharmaceutics from the Johann Wolfgang Goethe-University in Frankfurt in 1996. He joined the University of Alberta in 2000.  His research interests are in Biopharmaceutics to predict the oral performance of drugs and botanicals and inhalable nanoparticles to treat lung diseases like cancer or tuberculosis.  He is founder and director of the Drug Development and Innovation Centre at the University of Alberta.  He was president of the Canadian Society for Pharmaceutical Sciences 2014 & 2015 He is member of the United States Pharmacopeia Dietary Supplement Expert Committee.  He is Vice Chair of the Specialty Committee of Traditional Chinese Medicine in Pharmaceutics of the World Foundation of Chinese Medicine Science.  He is member of the Health Canada Scientific Advisory Committee on Pharmaceutical Sciences and Clinical Pharmacology.

Research Interest

Inhalable nanoparticles for pulmonary drug delivery of anti-cancer drugs: This research is performed in collaboration between Engineering, Medicine and Pharmacy. The first publication of this work has received the most cited award of the International Journal of Pharmaceutics in 2004. Our group published several review articles and original research articles (see googelscholar). A patent was issued about the technology. The preclinical application and the high potential of this delivery platform was published in 2011; showing that inhalable nanoparticles are much more potent compared to other routes of administration in lung cancer treatment. We recently applied the technology to tuberculosis.